Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
(NASDAQ: ORGO) Delayed: 2.43 --0 (-0%)
Previous Close $2.43    52 Week High $ 
Open $2.42    52 Week Low $ 
Day High $2.45    P/E N/A 
Day Low $2.32    EPS $ 
Volume 1,013,102